These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31581204)

  • 1. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
    Iwanuk N; Wall L; Nolte I; Raue J; Rumstedt K; Pilgram A; Sehn M; Rohn K; Bach JP
    PLoS One; 2019; 14(10):e0223164. PubMed ID: 31581204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N; Nolte I; Wall L; Sehn M; Raue J; Pilgram A; Rumstedt K; Bach JP
    BMC Vet Res; 2019 Jul; 15(1):237. PubMed ID: 31288807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
    Klein S; Nolte I; Rumstedt K; Sehn M; Raue JF; Weiner F; Treese JS; Beyerbach M; Bach JP
    BMC Vet Res; 2021 Sep; 17(1):310. PubMed ID: 34563187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F; Neves J; Maddox TW; Hodgkiss-Geere HM; Bode EF; Dukes-McEwan J
    Open Vet J; 2020 Jan; 9(4):375-383. PubMed ID: 32042661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension.
    Helms SR; Fox S; Mixon W; Vail J
    Int J Pharm Compd; 2012; 16(1):34-41. PubMed ID: 23050309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM; Menciotti G; Braz-Ruivo L; Crosara S; Häggström J; Borgarelli M
    Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
    Kaplan JL; Visser LC; Gunther-Harrington CT; Ontiveros ES; Wittenburg LA; Palm CA; Stern JA
    J Vet Intern Med; 2022 Nov; 36(6):1892-1899. PubMed ID: 36098206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
    McManamey AK; DeFrancesco TC; Meurs KM; Papich MG
    J Vet Intern Med; 2023; 37(6):2003-2010. PubMed ID: 37776546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques.
    Bagardi M; Palermo V; Locatelli C; Colombo FM; Pazzagli L; Brambilla PG
    Vet Res Commun; 2022 Jun; 46(2):481-486. PubMed ID: 35034282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
    Boswood A; Gordon SG; Häggström J; Vanselow M; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
    J Vet Intern Med; 2020 May; 34(3):1108-1118. PubMed ID: 32200574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom.
    Mattin MJ; Brodbelt DC; Church DB; Boswood A
    J Vet Intern Med; 2019 Mar; 33(2):445-454. PubMed ID: 30565334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
    J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease.
    Ouellet M; Bélanger MC; Difruscia R; Beauchamp G
    J Vet Intern Med; 2009; 23(2):258-63. PubMed ID: 19143935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echocardiographic evaluation of regurgitant fraction in dogs with subclinical myxomatous mitral valve disease: Method comparison, effects of pimobendan, and reproducibility.
    Ellis-Reis RE; Visser LC; Hsue W; Sharpe AN; Kaplan JL
    J Vet Cardiol; 2023 Feb; 45():27-40. PubMed ID: 36630740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.
    Lombard CW; Jöns O; Bussadori CM
    J Am Anim Hosp Assoc; 2006; 42(4):249-61. PubMed ID: 16822763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
    Franchini A; Borgarelli M; Abbott JA; Menciotti G; Crosara S; Häggström J; Lahmers S; Rosenthal S; Tyrrell W
    J Vet Cardiol; 2022 Jun; 41():99-120. PubMed ID: 35316716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.